Inhibition of Integrin aVb3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma

Abstract: Bexarotene is a specific retinoid X receptor agonist that has been used for the treatment of cutaneous T-cell lymphoma (CTCL). Because bexarotene causes hypothyroidism, it requires the administration of levothyroxine. However, levothyroxine, in addition to its ubiquitous nuclear receptors, can activate the aVb3 integrin that is overexpressed in CTCL, potentially interfering the antineoplastic effect of bexarotene. We thus investigated the biological effect of levothyroxine in relation to bexarotene treatment. Although in isolated CTCL cells levothyroxine decreased, in an aVb3-dependent manner, the antineoplastic effect of bexarotene, levothyroxine supplementation in preclinical models was necessary to avoid suppression of lymphoma immunity. Accordingly, selective genetic and pharmacologic inhibition of integrin aVb3 improved the antineoplastic effect of bexarotene plus levothyroxine replacement while maintaining lymphoma immunity. Our results provide a mechanistic rationale for clinical testing of integrin aVb3 inhibitors as part of CTCL regimens based on bexarotene administration.

Bibliographic Details

Main Authors:	Cayrol, María Florencia, Revuelta, Maria V., Debernardi, Maria Mercedes, Paulazo, Maria Alejandra, Phillip, Jude M., Zamponi, Nahuel, Sterle, Helena Andrea, Díaz Flaqué, María Celeste, Magro, Cynthia, Marullo, Rossella, Mulvey, Erin, Ruan, Jia, Cremaschi, Graciela A., Cerchietti, Leandro
Format:	Artículo biblioteca
Language:	spa
Published:	American Association for Cancer Research 2022
Subjects:	INMUNOLOGIA, LINFOMA DE CÉLULAS T, BEXAROTENO,
Online Access:	https://repositorio.uca.edu.ar/handle/123456789/15399
Tags:	Add Tag No Tags, Be the first to tag this record!